Purple Biotech Ltd

Key Insights

Purple Biotech Ltd's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 201 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 34.00.In the medium term, the stock price is expected to trend down.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.